IGI: FDA Approval And Commercial Launch Of Diclofenac Sodium, 1.5%

(RTTNews) - IGI Laboratories Inc (IG) on Thursday said it has launched its seventh product, diclofenac sodium 1.5% topical solution, after receipt of the final approval from the U.S. Food and Drug Administration for an abbreviated new drug application.

The company now markets seven products in twelve presentations in an IGI label.

Diclofenac sodium topical solution 1.5% is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain from osteoarthritis of the knee. Based on IMS Health data for May 2015, the total addressable market for this product is approximately $13.3 million.